Although the clinical relevance of your aforementioned cardiovascular threat factor alterations by tirzepatide might be assessed from the prepared cardiovascular consequence review SURPASS-CVOT ( "form":"clinical-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Assessment indic